Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Issues FY 2026 Earnings Guidance

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 1.251-1.400 for the period. The company issued revenue guidance of $52.4 billion-$54.7 billion, compared to the consensus revenue estimate of $53.9 billion.

Wall Street Analyst Weigh In

Several research analysts have commented on BAYRY shares. DZ Bank downgraded Bayer Aktiengesellschaft from a “strong-buy” rating to a “strong sell” rating in a report on Wednesday, February 18th. Morgan Stanley upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Wednesday, December 3rd. Barclays upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Tuesday, January 6th. Zacks Research lowered shares of Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a report on Monday, February 23rd. Finally, JPMorgan Chase & Co. upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research note on Monday, December 8th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Bayer Aktiengesellschaft currently has a consensus rating of “Moderate Buy”.

Bayer Aktiengesellschaft Price Performance

Shares of BAYRY stock opened at $10.97 on Wednesday. The firm has a market capitalization of $43.11 billion, a price-to-earnings ratio of -121.88, a PEG ratio of 4.67 and a beta of 0.69. Bayer Aktiengesellschaft has a fifty-two week low of $5.30 and a fifty-two week high of $14.85. The stock’s 50-day simple moving average is $12.42 and its 200-day simple moving average is $9.87. The company has a debt-to-equity ratio of 1.10, a quick ratio of 0.71 and a current ratio of 1.14.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.